期刊档案 · INFECTIOUS DISEASES
Infection and Chemotherapy
ISSN 2093-2340 · eISSN 2092-6448 · Jin Publishing & Printing Co. · Korea, Republic of
Infection and Chemotherapy 中科院 医学 4区（2025 年升级版），钻石开放获取（无 APC），免版面费，近 24 个月 100 篇文章投稿到接收中位 65 天，2025 年发文 86 篇，ESCI、Scopus 收录，期刊官网显示已更换出版社。
期刊官网显示已更换出版社：Infect Chemother provides the electronic backup and preservation of access to the journal content in the event the journal is no longer published by archiving in PubMed Central and KoreaMed. 原文 ↗出版商官网 ·
研究范围
研究范围与定位
Infection and Chemotherapy 由 Jin Publishing & Printing Co. 出版，属中科院医学大类（2025 升级版4区）。按 OpenAlex 近年发文统计，该刊主要发表 Antibiotic Resistance in Bacteria、Bacterial Identification and Susceptibility Testing、SARS-CoV-2 and COVID-19 Research 等主题的论文，这 3 个主题约占 17.5%，主导子领域为 Infectious Diseases。（根据 OpenAlex 主题统计与中科院分区数据生成）
Infection & Chemotherapy (Infect Chemother) is an international, peer-reviewed, and open-access journal in English, which publishes the current research on issues posed by infectious diseases worldwide. Its regional focus is mainly Korea, but Infect Chemother welcomes submissions from researches all over the world. This journal, which is published quarterly (on the last day of March, June, September, and December) in both print and online (https://www.icjournal.org) versions, is the only official publication of the Korean Society of Infectious Diseases (http://www.ksid.or.kr/), Korean Society for Antimicrobial Therapy (formerly Korean Society for Chemotherapy) (http://www.ksat.or.kr/), the Korean Society for AIDS (http://www.kosaids.or.kr/) and Korean Society of Pediatric Infectious Diseases (https://www.kspid.or.kr/). It publishes review articles, original articles, brief communications, correspondences, case reports, editorials, and special articles covering an extensive range of clinical descriptions on infectious diseases, public health issues, microbiology including emerging resistance, parasitology and immunity to microbes, current and novel treatments, antimicrobial stewardship, and the promotion of optimal practices or guidelines for diagnoses and treatments representative of Korea and other countries or academic societies. Infect Chemother also covers the emerging and niche fields of infectious diseases such as multidrug resistant bacterial diseases, new drugs and vaccines, pandemic or emerging viral diseases, infectious diseases that are prevalent only in East Asia including Korea, and infectious diseases that have been forgotten. As the world continues to shrink as a result of globalization, it is necessary that appropriate communication is maintained among countries for timely sharing of information on infectious diseases. This is an important topic because such diseases tend to have unique biologic features according to the regions in which they develop, and these diseases can easily become nidus that may spread globally at any time. Based on these factors, the aim of this publication is to facilitate communication among societies and countries, enabling the worldwide sharing of information on infectious diseases. The scope of this journal is to link basic and clinical research in the field of infectious diseases, in reference to relevant evidence. The journal continuously attempts to publish current global and regional topics concerning infec
摘自期刊官网 Aims & Scope
研究方向（LetPub）：INFECTIOUS DISEASES
主编 Wan Beom出版商官网
编委会国家分布：中国大陆 1 位（约 2%）；主要国家 韩国 34、美国 6、日本 2、中国 1、中国台湾 1（共 55 位编委标注了国家） 编委会 ↗出版商官网 ·
主要研究主题 OpenAlex 近年发文统计，占比为近似值
- Antibiotic Resistance in BacteriaBiochemistry, Genetics and Molecular Biology6.8%
- Bacterial Identification and Susceptibility TestingBiochemistry, Genetics and Molecular Biology5.8%
- SARS-CoV-2 and COVID-19 ResearchMedicine4.9%
- Respiratory viral infections researchMedicine4.7%
- COVID-19 Clinical Research StudiesMedicine4.6%
- Antimicrobial Resistance in StaphylococcusMedicine4.6%
- Antibiotic Use and ResistanceImmunology and Microbiology4.6%
- Streptococcal Infections and TreatmentsMedicine4.5%
分区与收录
学科分区与数据库收录
中科院期刊分区表
期刊分区表（ 2025年3月升级版）医学 4 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 4 区 |
| 小类 | 传染病学INFECTIOUS DISEASES | 4 区 |
Top 期刊：否综述期刊：否
《新锐期刊分区表》（ 2026年3月发布）医学 3 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 3 区 |
| 小类 | 传染病学INFECTIOUS DISEASES | 4 区 |
Top 期刊：否综述期刊：未标注
期刊分区表（ 2023年12月旧的升级版）未收录
该期刊未被此版本分区表收录。
数据库收录
ESCIScopusDOAJLetPub
国际期刊预警名单：各版本均未列入LetPub
期刊官网自述收录
PMCPubMedEmbaseCAS出版商官网
其他：Google Scholar、Crossref、Crossref and DOI、CABI、KoreaMed Synapse、KoMCI
期刊官网列出的收录清单，未与各数据库逐一核对；Web of Science 各子库以上方记录为准。
不同版本、大类与小类分别展示，不将不同评价口径合并为一个分区值；投稿与考核前请确认所在机构采用的版本。
指标
影响力指标与发文规模
影响力指标
- CiteScore 2026-06
- 5.1LetPub ·
- SJR 2026-06
- 0.72LetPub ·
- SNIP 2026-06
- 0.83LetPub ·
- h-index
- 51OpenAlex ·
- i10-index
- 405OpenAlex ·
- 两年平均被引
- 2.58OpenAlex ·
- 自引率
- 8.3%LetPub ·
- Gold OA 文章占比
- 97.53%LetPub ·
发文规模
- 年文章数
- 59LetPub ·
逐年发文量 OpenAlex 统计 · 累计 1,474 篇 · 当年数据不完整
| 年份 | 发文量 | 其中 OA | 被引 |
|---|---|---|---|
| 2026 | 53 | 53 | 7 |
| 2025 | 86 | 86 | 141 |
| 2024 | 71 | 71 | 394 |
| 2023 | 65 | 65 | 420 |
| 2022 | 101 | 101 | 1,076 |
| 2021 | 92 | 92 | 1,275 |
不同来源的统计口径与观测时间不同，页面保留各来源原值；“出版商公布”为期刊官网自述数据。
审稿与录用
审稿周期与录用情况
文章统计的审稿周期 Crossref 登记的稿件日期 · 至
65 天投稿到接收中位数 · P25–P75 32 天 – 85 天
- 接收到上线
- 中位数 51 天（101 篇）
- 投稿到上线
- 中位数 122 天
- 样本
- 100 篇有投稿与接收日期的文章（窗口内共 137 篇），最近一篇接收于
只统计最终被录用并发表的文章，不含被拒稿件的处理时间，因此通常长于出版商公布的"首次决定时间"。
其他来源
- 平均审稿速度（社区反馈）
- 22 WeeksLetPub ·
- 投稿到发表（期刊自报）
- 约 22 周DOAJ ·
- 评审方式
- 双盲同行评审DOAJ
社区反馈来自投稿者样本，置信度 0.5，不代表期刊承诺；“出版商公布”的时间节点定义以官网为准。
费用与开放获取
版面费与开放获取政策
钻石开放获取（无 APC）DOAJ
所有文章开放获取，且不向作者收取文章处理费。
| 来源 | 文章处理费 | 费用减免 | 许可证 | 观测时间 |
|---|---|---|---|---|
| DOAJ | 无文章处理费 | 无 | CC BY-NC | |
| OpenAlex | USD 200 | — | — | |
| LetPub | USD 200 | 无 | — | |
| 出版商官网 | 有，金额未公布 | — | — |
其他费用与减免（作者指南）
- 版面费
- 收取，金额见官网
- APC 费用说明 ↗DOAJ
- 开放获取声明 ↗DOAJ
- 许可与版权 ↗DOAJ
费用以期刊官网为准；不同来源的观测时间可能不同，页面保留各来源原值，不做平均。
投稿要求
文章类型与投稿政策（官网）
投稿准备要点6 项，摘自作者指南
- 摘要
- ≤ 400 词
- 关键词
- ≤ 5 个
- 正文篇幅
- ≤ 5,500 词
- 参考文献格式
- Vancouver 格式
- 图文摘要
- 可选
- 投稿信（Cover letter）
- 必须提供
接收的文章类型13 种，含篇幅限制
- brief communicationARTICLE DESCRIPTION ABSTRACT WORD LIMIT TABLES/FIGURES REFERENCES Review Article Review articles are usually solicited by the Editor-in-Chief. Authors should co…正文 ≤ 1,500 词 · 摘要 ≤ 100 词 · 图表 ≤ 3
- correspondenceARTICLE DESCRIPTION ABSTRACT WORD LIMIT TABLES/FIGURES REFERENCES Review Article Review articles are usually solicited by the Editor-in-Chief. Authors should co…正文 ≤ 500 词 · 图表 ≤ 1
- editorialARTICLE DESCRIPTION ABSTRACT WORD LIMIT TABLES/FIGURES REFERENCES Review Article Review articles are usually solicited by the Editor-in-Chief. Authors should co…正文 ≤ 1,200 词 · 图表 ≤ 1
- letterARTICLE DESCRIPTION ABSTRACT WORD LIMIT TABLES/FIGURES REFERENCES Review Article Review articles are usually solicited by the Editor-in-Chief. Authors should co…未说明篇幅
- letters to the editorARTICLE DESCRIPTION ABSTRACT WORD LIMIT TABLES/FIGURES REFERENCES Review Article Review articles are usually solicited by the Editor-in-Chief. Authors should co…未说明篇幅
- literature reviewARTICLE DESCRIPTION ABSTRACT WORD LIMIT TABLES/FIGURES REFERENCES Review Article Review articles are usually solicited by the Editor-in-Chief. Authors should co…未说明篇幅
- meta-analysisARTICLE DESCRIPTION ABSTRACT WORD LIMIT TABLES/FIGURES REFERENCES Review Article Review articles are usually solicited by the Editor-in-Chief. Authors should co…未说明篇幅
- obituaryInfect Chemother recognizes and honors our deceased members and their contributions to our society and to infectious diseases at large.未说明篇幅
- original articleARTICLE DESCRIPTION ABSTRACT WORD LIMIT TABLES/FIGURES REFERENCES Review Article Review articles are usually solicited by the Editor-in-Chief. Authors should co…正文 ≤ 5,500 词 · 摘要 ≤ 400 词
- original research articleARTICLE DESCRIPTION ABSTRACT WORD LIMIT TABLES/FIGURES REFERENCES Review Article Review articles are usually solicited by the Editor-in-Chief. Authors should co…未说明篇幅
- reviewARTICLE DESCRIPTION ABSTRACT WORD LIMIT TABLES/FIGURES REFERENCES Review Article Review articles are usually solicited by the Editor-in-Chief. Authors should co…未说明篇幅
- review articleARTICLE DESCRIPTION ABSTRACT WORD LIMIT TABLES/FIGURES REFERENCES Review Article Review articles are usually solicited by the Editor-in-Chief. Authors should co…正文 ≤ 6,500 词 · 摘要 ≤ 200 词
- special articleSpecial articles are invited with an intention for special introduction of medical issues and any interesting information such as practice guidelines.未说明篇幅
官网政策摘录作者资格、利益冲突、数据可用性、许可与版权、开放获取、同行评审、查重、预印本
- 作者资格 Authorship Policy
作者身份认定遵循ICMJE（2025）和KAMJE（2019）的指南，基于对工作的实质性贡献、起草或批判性修改、最终批准以及问责等标准。 模型中文摘要
The Infect Chemother follows the recommendations for authorship by ICMJE (2025, http://www.icmje.org/icmje-recommendations.pdf) and Good Publication Practice Guidelines by KAMJE (2019, https://www.kamje.or.kr/board/view?b_name=bo_publication&bo_id=13&per_page=). The uniform requirements by the ICMJE recommend authorship as follows. Authorship credit should be based on 1) Substantial contributions …
原文 ↗出版商官网 ·- 利益冲突 Conflict of Interest
通讯作者须告知编辑可能影响数据解读的潜在利益冲突，即使作者确信其判断未受影响，也应在投稿信中披露。 模型中文摘要
The corresponding author of an article is asked to inform the Editor of the authors’ potential conflicts of interest possibly influencing their interpretation of data. A potential conflict of interest should be disclosed in the cover letter even when the authors are confident that their judgments have not been influenced in preparing the manuscript. Such conflicts may be financial support or priva…
原文 ↗出版商官网 ·- 数据可用性 DATA SHARING STATEMENT
自2018年7月1日起，报告临床试验结果的所有稿件均须按照ICMJE指南提交数据共享声明。 模型中文摘要
Infect Chemother accepts the ICMJE Recommendations for data sharing statement policy (http://icmje.org/icmje-recommendations.pdf). All manuscripts reporting clinical trial results should submit a data sharing statement following the ICMJE guidelines from 1 July 2018. As one of the members of KAMJE, Infect Chemother agrees with the editorial, “Data Sharing statements for Clinical Trials: A Requirem…
原文 ↗出版商官网 ·- 许可与版权 COPYRIGHT AND CREATIVE COMMONS ATTRIBUTION LICENSE
发表条件是作者向期刊主办学会授予专有许可，并遵循知识共享署名-非商业性使用许可协议；商业使用须获得许可。 模型中文摘要
It is a condition of publication in Infect Chemother that the authors grant an exclusive license to the journal’s sponsoring society, the Korean Society of Infectious Diseases, Korean Society for Antimicrobial Therapy, Korean Society for AIDS, and Korean Society of Pediatric Infectious Diseases. They also follow the Creative Commons Attribution Non-Commercial License available from: http://creativ…
原文 ↗出版商官网 ·- 开放获取 OPEN ACCESS POLICY
本刊为开放获取期刊，所有内容免费提供，用户可阅读、下载、复制、分发、打印、搜索或链接全文，无需事先征得出版商或作者许可。 模型中文摘要
Infect Chemother is an open access journal which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI …
原文 ↗出版商官网 ·- 同行评审 EDITORIAL AND PEER REVIEW PROCESS
所有来稿均经评审；稿件先经格式和学术相关性预审，再经iThenticate查重（通常阈值为15%），随后送交至少两名相关研究者进行匿名同行评审。 模型中文摘要
Peer Review Process Infect Chemother reviews all manuscripts received. A manuscript is previewed for its format and academic relevancy. If the manuscript does not fit the aims and scope of Infect Chemother or does not adhere to the Instructions to Authors, it may be returned to the author immediately after receipt and without a review. Before reviewing, all submitted manuscripts are inspected by S…
原文 ↗出版商官网 ·- 查重 Redundant Publication and Plagiarism
重复发表被定义为在未注明原始来源的情况下，多次报告（发表或试图发表）实质上相同的工作。 模型中文摘要
Redundant publication is defined as “reporting (publishing or attempting to publish) substantially the same work more than once, without attribution of the original source (s)”. Characteristics of reports that are substantially similar include the following: (a) “at least one of the authors must be common to all reports (if there are no common authors, it is more likely plagiarism than redundant p…
原文 ↗出版商官网 ·- 预印本 PREPRINT POLICY
允许提交已在medRxiv、bioRxiv或类似平台预印的稿件，但建议作者在投稿过程中通过DOI在标题页予以披露，否则可能会被查重程序筛查。 模型中文摘要
A preprint can be defined as a version of a scholarly paper that precedes formal peer review and publication in a peer-reviewed scholarly journal. Preprinted manuscripts in medRxiv, bioRixv or similar platforms are allowed to submit is allowed to Infect Chemother under provisions. Infect Chemother recommend authors to disclose it with DOI in the title page during the submission process. Otherwise,…
原文 ↗出版商官网 ·
摘录来自期刊官网页面，仅保留原文片段；“模型摘要”由 Workers AI 生成并经原文校验，以官网为准。
基本信息
出版信息与官方入口
- 出版商
- Jin Publishing & Printing Co.
- 出版国家或地区
- Korea, Republic of
- 出版语言
- English
- ISSN
- 2093-2340
- 电子版 ISSN
- 2092-6448
- 官网最新一期
- Volume 58, Issue 2（2026 年 6 月）
- 官方链接
- 期刊主页 ↗LetPub
- 投稿系统 ↗出版商官网
- 作者指南 ↗DOAJ
- Aims & Scope ↗DOAJ
- APC 费用说明 ↗DOAJ
- 开放获取声明 ↗DOAJ
- 许可与版权 ↗DOAJ
- 评审流程 ↗DOAJ
- 编委会 ↗DOAJ
- 查重政策 ↗DOAJ
常见问题
关于 Infection and Chemotherapy 的常见问题
Infection and Chemotherapy 是中科院几区期刊？
2025 年升级版分区表中，Infection and Chemotherapy 为医学 4区，小类 传染病学 4 区。2026 年新锐版分区表中为医学 3区。不同版本与大小类分区不能混用。
Infection and Chemotherapy 的审稿周期多长？
按 2024年10月至2026年10月（近 24 个月）100 篇已发表文章登记的日期，投稿到接收的中位数为 65 天（四分位 32–85 天）；投稿社区反馈的平均审稿速度为约 22 周。文章统计只含被录用的稿件，出版商数据口径以官网为准，社区反馈来自投稿者样本，均不代表期刊承诺。
Infection and Chemotherapy 的投稿格式要求是什么？
据期刊作者指南：摘要：≤ 400 词；关键词：≤ 5 个；正文篇幅：≤ 5,500 词；参考文献格式：Vancouver 格式；图文摘要：可选；投稿信：必须提供。以上由模型从作者指南提取并逐项与原文核对，投稿前请以官网最新版本为准。
Infection and Chemotherapy 的编委会里有中国学者吗？
期刊官网编委会页面上标注了国家的 55 位编委中，中国大陆 1 位（约 2%）；人数最多的国家是 韩国（34 位）、美国（6 位）、日本（2 位）。统计按编委会页面列出的机构国家计，仅供参考。
Infection and Chemotherapy 被哪些数据库收录？
据 LetPub 与 DOAJ 记录，Infection and Chemotherapy 被 ESCI、Scopus、DOAJ 收录。期刊官网自述还被 PMC、PubMed、Embase、CAS 收录，该清单未与各数据库逐一核对。
Infection and Chemotherapy 是开放获取期刊吗？版面费多少？
Infection and Chemotherapy 为钻石开放获取（无 APC）。不收取文章处理费。
来源与更新
本页事实来自 LetPub、OpenAlex、DOAJ、出版商官网；每个数字旁标注来源与观测日期，冲突数据保留各来源原值。LetPub 原始详情页：查看 ↗（2026-08-25 归档）。最近更新：。